Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology reported encouraging Phase 1 data for OP-3136, a novel KAT6 inhibitor, at the ASCO Annual Meeting. The drug showed a manageable safety profile with no dose-limiting toxicities up to 45 mg and no discontinuations due to adverse events.
Key figures
- Drug Name
- OP-3136
- Phase Of Trial
- Phase 1
- Patients enrolled
- 32
- Max dose evaluated mg
- 45
- Anemia incidence any grade
- 38%
- Confirmed partial responses
- 2
- Response evaluable patients
- 19
- Dysgeusia incidence any grade
- 81%
- Patients with tumor shrinkage
- 13
- Unconfirmed partial responses
- 1
- Neutropenia incidence any grade
- 34%
- Patients remaining on treatment
- 11
- Longest treatment duration weeks
- 62
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.